After a conference lacking the wow factor, biotech winners and losers emerge.
ApexOnco Front Page
Recent articles
Despite seeing dose-limiting toxicities, the group is going higher with its KRAS G12D project.
Merck turns to China for a molecule against one of biopharma’s most extensively studied antigens.
Following its odronextamab knockback, Regeneron now faces a delay to linvoseltamab.
Keyvibe-008 is halted for futility, an outcome that might have been foreseen in 2022.
First-in-human trial initiations feature Interius, Umoja and Vironexis.
BioNTech and Genmab's acasunlimab is the latest 4-1BB project to stumble.
NVL-330 features among the latest crop of industry projects newly into human trials.
